MEDI-3617 (anti-ANGPT2) is a human monoclonal antibody directed against the angiogenic cytokines angiopoietin-2 (Angpt2). MEDI-3617 (anti-ANGPT2) in combination with tremelimumab is used to treat advanced melanoma.Purity≥95% (SDS-PAGE&SEC)Endotoxin Level≤1.0EU/mgProtein FunctionCan induce tyrosine phosphorylation of TIE2. Binds to TIE2 receptor and counteracts blood vessel maturation/stability mediated by angiopoietin-1. Its function may be context-dependent. In the absence of angiogenic inducers, such as VEGF, ANG2-mediated loosening of cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In concert with VEGF, it may facilitate endothelial cell migration and proliferation, thus serving as a permissive angiogenic signal.
Specification: Carrier Free, ExactAb™, Low Endotoxin, Azide Free, Validated, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/AB183134-SCI_18cef7ddea8e426129bf5c8584bed8bf.pdf
- UPC:
- 51434200
- Condition:
- New
- Availability:
- 4-8 weeks
- Weight:
- 0.07 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- Ab183134-10mg
- Product Size:
- 10mg
